Methylene blue photoinactivation of RNA viruses

We present a review of the current status of the use of methylene blue (MB) photoinactivation of viruses starting with the first early observations up to its current use to inactivate HIV-1 in blood products. Basic mechanism of action studies conducted with model bacteriophages indicate that MB-phot...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral Research 2004-03, Vol.61 (3), p.141-151
Main Authors: Floyd, Robert A, Schneider, J.Edward, Dittmer, Dirk P
Format: Article
Language:English
Subjects:
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - pharmacology
Biological and medical sciences
Blood - virology
HIV
HIV-1 - drug effects
Human immunodeficiency virus 1
Light
Medical sciences
Methylene blue
Methylene Blue - pharmacology
Pharmacology. Drug treatments
Photoinactivation
Photosensitizing Agents - pharmacology
RNA viruses
RNA Viruses - drug effects
Virus Inactivation
West Nile Virus
West Nile virus - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We present a review of the current status of the use of methylene blue (MB) photoinactivation of viruses starting with the first early observations up to its current use to inactivate HIV-1 in blood products. Basic mechanism of action studies conducted with model bacteriophages indicate that MB-photomediated viral RNA-protein crosslinkage is a primary lesion and that oxygen, specifically singlet oxygen, is very important also. Basic studies on the mechanism of action with HIV are lacking; however, we do show new data illustrating that viral reverse transcriptase inactivation per se cannot account for MB-mediated photoinactivation. We also show data illustrating that MB photomediates the inactivation of West Nile Virus, a flavivirus, which poses a significant new threat to the continental US. MB photoinactivation of viruses show significant promise because the technology not only offers significant potency but the history of safe MB use in human therapy makes it attractive also.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2003.11.004